FORT WORTH, Texas - Omnicell , Inc. (NASDAQ:OMCL) reported better-than-expected fourth quarter earnings and revenue, but its stock tumbled 4.7% in after-hours trading due to disappointing guidance for the first quarter and full year 2025.
The medication management technology company posted adjusted earnings per share of $0.60, surpassing analyst estimates of $0.58. Revenue for the quarter came in at $306.88 million, exceeding the consensus forecast of $299.6 million and representing a 19% YoY increase.
Despite the solid Q4 performance, Omnicell’s outlook fell short of expectations. The company projects first quarter 2025 EPS between $0.15 and $0.25, below the $0.31 consensus. Q1 revenue guidance of $255-265 million also missed the $264.9 million analyst estimate at the midpoint.
For the full year 2025, Omnicell expects EPS of $1.65-$1.85 on revenue of $1.1-1.15 billion. While the EPS guidance midpoint of $1.75 is above the $1.69 consensus, the revenue outlook falls short of the $1.15 billion analyst projection.
Randall Lipps, chairman, president, CEO, and founder of Omnicell, commented on the results: "We delivered solid financial results for the fourth quarter of 2024, including returning to YoY revenue growth. We are pleased with the improved execution of the business throughout 2024, including strong free cash flows achieved in the year."
The company’s total bookings for 2024 increased 8% YoY to $923 million, driven by XT Series upgrades and better-than-expected bookings of XTExtend, a core component of the multi-year XT Amplify innovation program.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.